Catalog number: 468 - 21511011-1
Product Category: Business & Industrial > Science & Laboratory
Size: null
79973
The activation of naíve T cells requires two signals, the specific T cell receptor recognition of MHC/Antigen on the surface of the antigen-presenting cell (APC), and the binding of B7-1 (CD80) ligand on the APC with the CD28 receptor on the T cell surface. Conversely, binding of CTLA4 to B7-1 on the T-cell surface results in an inhibitory signal and prevents T-cell activation. CTLA4B7-1 interaction is an important drug target for the regulation of the host's response to cancer. The CTLA4 [Biotinylated]:B7-1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-1 signaling. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-1 is coated on a 96-well plate. Next, CTLA4[B] is incubated with B7-1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.
EP-131-96tests
CD155 and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways. TIGIT, an inhibitory receptor, is mainly expressed on natural killer (NK), CD8+ T, CD4+ T and T regulatory (Treg) cells. CD155 transmits immune signals via interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting the function of T and NK cells.CD155 is highly expressed on the surface of DC cells. When TIGIT on T cells binds to CD155 on DC cells, CD155 will send signals to DC cells to up-regulate the secretion of IL-10 and down-regulate the secretion of IL-12, thereby weakening the immune response mediated by DC cells. DC cells are important antigen-presenting cells in the body, and reduced DC cell activity in turn reduces T cell activity.
EP-135
CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily, and the physiological functions of CD30 are in addition to the transmission of synergistic stimulation signals. CD30 ligand (CD30L) belongs to the tumor necrosis factor (TNF) superfamily, and CD30L is present in activated T cells, quiescent B cells, granulocytes, thymic medullary cells, and various leukemia cells. After crosslinking CD30 and CD30L, diverse physiological function signaling is led by TNFR correlation factors (TRAF), including TRAF1, 2, 3, 5. CD30 was originally found in Hodgkin's lymphoma and Reed Sternberg (RS) cells, and is now known to be expressed on the surface of some normal lymphocytes, virally infected lymphocytes, lymphocytes of lymphogenetic origin, and activated T cell subsets that produce Th2 cytokines.
EP-135-96tests
CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily, and the physiological functions of CD30 are in addition to the transmission of synergistic stimulation signals. CD30 ligand (CD30L) belongs to the tumor necrosis factor (TNF) superfamily, and CD30L is present in activated T cells, quiescent B cells, granulocytes, thymic medullary cells, and various leukemia cells. After crosslinking CD30 and CD30L, diverse physiological function signaling is led by TNFR correlation factors (TRAF), including TRAF1, 2, 3, 5. CD30 was originally found in Hodgkin's lymphoma and Reed Sternberg (RS) cells, and is now known to be expressed on the surface of some normal lymphocytes, virally infected lymphocytes, lymphocytes of lymphogenetic origin, and activated T cell subsets that produce Th2 cytokines.